ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Jennifer L. Ellis
Michael E. Burt
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Port, J. L.
Right arrow Articles by Burt, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Port, J. L.
Right arrow Articles by Burt, M. E.

Ann Thorac Surg 1996;62:848-852
© 1996 The Society of Thoracic Surgeons


Original Articles: General Thoracic

Isolated Lung Perfusion With FUDR in the Rat: Pharmacokinetics and Survival

Jeffrey L. Port, MD, Bruce Ng, MS, Jennifer L. Ellis, MD, Sumihiko Nawata, MD, Jeffrey T. Lenert, MD, Michael E. Burt, MDPhD

Thoracic Oncology/Surgical Metabolism Laboratory, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York

Accepted for publication April 28, 1996.

Background. Although surgical resection remains the mainstay of treatment for metastatic pulmonary colorectal cancer, 5-year survival approaches only 30% to 40%. We have developed a model of isolated left lung perfusion (ILP) with FUDR (2`-deoxy-5-fluorouridine) for the treatment of pulmonary colorectal metastases. FUDR ILP toxicity and pharmacokinetics were evaluated and compared with continuous intravenous infusion in the rat.

Methods. Toxicity was first evaluated in F344 rats (n = 17) after left ILP (20-minute perfusion at 0.5 mL/min) with 21 mg/mL (n = 11), 28 mg/mL (n = 2), 35 mg/mL (n = 2), and 70 mg/mL (n = 2) of FUDR. Animals were followed up and weights recorded for 14 days postoperatively before a right pneumonectomy was performed to evaluate the effect of FUDR perfusion on left lung function. In the second study, 32 rats (n = 8/group) underwent: systemic FUDR (intravenous), or ILP with 7, 14, and 21 mg/mL respectively (ILP 7, ILP 14, and ILP 21 groups). Left lungs and serum were analyzed for FUDR and 5-fluorouracil by high-performance liquid chromatography.

Results. Rats perfused with doses of FUDR greater than 21 mg/mL died perioperatively. All animals perfused at 21 mg/mL survived until day 14, and 8/11 survived a right pneumonectomy. Rats that survived ILP resumed normal weight gain and grooming habits within 1 week. Pharmacokinetic evaluation demonstrated that ILP at 21 mg/mL maximally elevated total lung FUDR and 5-fluorouracil levels (508.5 ± 96.4 µg/g lung) in comparison with the ILP 14, ILP 7, and intravenous groups (299.1 ± 44.8, 116.0 ± 21.1, and 7.5 ± 4.1 µg/g lung, respectively) (p< 0.05). Serum FUDR levels were 10.5 ± 6.8, 1.3 ± 0.5, 2.31 ± 1.1, and 1.2 ± 0.4 µg/g lung (p = not significant) for intravenous, ILP 7, ILP 14, and ILP 21 groups, respectively.

Conclusions. Isolated left lung perfusion with FUDR is well tolerated to a maximum dose of 21 mg/mL and results in significantly higher FUDR and 5-fluorouracil lung levels with low serum levels compared with intravenous treatment. These higher pulmonary levels may offer advantages in the treatment of pulmonary colorectal metastases.




This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
S. Romijn, J. M.H. Hendriks, B. P. Van Putte, J. Weyler, G. Guetens, G. De Boeck G, E. A. De Bruijn, and P. E.Y. Van Schil
Anterograde versus retrograde isolated lung perfusion with melphalan in the WAG-Rij rat
Eur. J. Cardiothorac. Surg., June 1, 2005; 27(6): 1083 - 1085.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
B. P. Van Putte, J. M. H. Hendriks, S. Romijn, B. Pauwels, G. De Boeck, G. Guetens, E. De Bruijn, and P. E. Y. Van Schil
Pharmacokinetics after pulmonary artery perfusion with gemcitabine
Ann. Thorac. Surg., October 1, 2003; 76(4): 1036 - 1040.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. M. Dupertuis, M. Vazquez, J.-P. Mach, N. De Tribolet, C. Pichard, D. O. Slosman, and F. Buchegger
Fluorodeoxyuridine Improves Imaging of Human Glioblastoma Xenografts with Radiolabeled Iododeoxyuridine
Cancer Res., November 1, 2001; 61(21): 7971 - 7977.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1996 by The Society of Thoracic Surgeons.